-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25

Benzinga·04/21/2025 10:08:07
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $7.25.